Valeant (VRX) has agreed to acquire Medicis (MRX), a provider of dermatological and aesthetic...

|About: Valeant Pharmaceuticals I... (VRX)|By:, SA News Editor

Valeant (VRX) has agreed to acquire Medicis (MRX), a provider of dermatological and aesthetic pharmaceutical products, for $2.6B, Valeant said yesterday. The firm's offer of $44/share represents a 39% premium to Medicis' close on Friday. The transaction is the latest in a long list of acquisitions for Valeant, which has secured around 50 deals since Michael Pearson became CEO in 2008. (PR).